IDEXX Laboratories, a leading player in the veterinarian health sector, has consistently outperformed the market, showcasing its remarkable growth potential. Over the span of 15 years, from 2008 to 2023, the company has generated an impressive average annual return of 25.91%.
To put this into perspective, let’s imagine an investor who had purchased $100 worth of IDXX stock back in 2008. Fast forward to November 20, 2023, and that investment would have skyrocketed to a staggering $3,108.09, considering the current price of $463.69 per IDXX share.
One of the key factors contributing to IDEXX Laboratories’ success is its consistent compound earnings per share (EPS) growth. Over the past five years, the company has experienced an impressive 22% annual growth rate in EPS, showcasing its ability to generate sustainable profits.
Moreover, IDEXX Laboratories has witnessed remarkable double-digit revenue growth in recent years, solidifying its position as a dominant player in the veterinarian health sector. This growth has been instrumental in driving the company’s stock performance and attracting investors seeking lucrative opportunities.
Looking back over the past decade, IDXX stock has delivered exceptional returns, nearing an astounding 1,000%. This translates to an impressive average annual return of approximately 25%, with a standard deviation of 29%, highlighting the stock’s stability and consistent performance.
As we approach 2023, IDXX stock has already achieved a remarkable return of 221.7% since 2018, with the highest annual return of 91.4% recorded in 2020. These figures showcase the company’s ability to adapt and thrive, even during challenging times.
Overall, IDEXX Laboratories has proven itself as a force to be reckoned with in the veterinarian health sector, consistently surpassing market expectations and delivering exceptional returns for its investors. With its strong track record and promising growth prospects, the company continues to attract attention and inspire confidence in the market.
IDEXX Laboratories, Inc.
Updated on: 30/11/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
IDXX Stock: Stable Performance on November 20, 2023 with Positive Earnings and Revenue Growth
On November 20, 2023, IDXX stock (IDEXX Laboratories Inc.) opened at $461.30, slightly lower than the previous day’s close of $463.69. Throughout the day, the stock’s price fluctuated between a low of $459.55 and a high of $473.84. The trading volume for the day was 21,095 shares, significantly lower than the average volume of 484,655 shares over the past three months. IDXX has a market capitalization of $38.8 billion.
IDXX reported a decline of 7.11% in earnings growth in the previous year. However, this year, the company has shown positive growth with a 20.94% increase in earnings. Looking ahead, IDXX is expected to continue its growth trajectory with a projected earnings growth of 18.04% over the next five years.
IDXX also experienced revenue growth of 4.73% in the last year. This indicates that the company’s business is expanding. The P/E ratio for IDXX stock is 48.2, suggesting that investors are willing to pay a premium for the company’s earnings.
The price/sales ratio for IDXX is 10.25, indicating that investors are valuing the company’s sales at a higher multiple compared to its competitors. The price/book ratio is 63.54, further highlighting the premium investors are willing to pay for IDXX’s assets.
On November 20, 2023, IDXX stock experienced a slight decrease of 0.33, resulting in a percentage change of -1.01%.
Looking ahead, IDXX is scheduled to release its next earnings report on January 31, 2024. Analysts are forecasting an EPS (earnings per share) of $2.27 for the current quarter. In the previous year, IDXX reported annual revenue of $3.4 billion and a profit of $679.1 million, resulting in a net profit margin of 20.17%.
IDXX operates in the Health Technology sector, specifically in the Medical Specialties industry. The company is headquartered in Westbrook, Maine.
Overall, the performance of IDXX stock on November 20, 2023, was relatively stable, with a slight decrease in value for the day. However, the company has shown positive earnings and revenue growth, indicating a promising outlook for the future.
IDEXX Laboratories Inc: Strong Stock Performance and Positive Outlook from Analysts
IDEXX Laboratories Inc, a leading provider of veterinary diagnostic and software solutions, has been performing well in the stock market. On November 20, 2023, the stock closed at a price of $473.17. However, analysts are optimistic about the future performance of the stock, with a median target price of $525.00, representing a potential increase of 10.95%.
According to CNN Money, there are 9 analysts offering 12-month price forecasts for IDEXX Laboratories Inc. The highest estimate is $600.00, while the lowest estimate is $440.00. This wide range of estimates suggests a level of uncertainty among analysts, but the median estimate of $525.00 indicates a positive outlook for the stock.
The consensus among 12 polled investment analysts is to buy stock in IDEXX Laboratories Inc. This rating has remained unchanged since November, indicating a consistent belief in the company’s growth potential.
In terms of financial performance, IDEXX Laboratories Inc reported earnings per share of $2.27 for the current quarter. Additionally, the company reported sales of $913.0 million for the same period.
Investors should keep an eye on IDEXX Laboratories Inc’s upcoming reporting date, which is scheduled for January 31. This will provide further insights into the company’s financial performance and may impact the stock’s future trajectory.
Overall, IDEXX Laboratories Inc has been performing well in the stock market, with a positive outlook from analysts and a consensus buy rating. However, investors should always conduct thorough research and consider their own investment goals and risk tolerance before making any investment decisions.